Avoparcin used as a growth promoter is associated with the occurrence of vancomycin-resistant Enterococcus faecium on Danish poultry and pig farms

Flemming Bager, M. Madsen, J. Christensen, Frank Møller Aarestrup

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

We determined the association between the use of the glycopeptide antibiotic avoparcin as a growth promoter and the occurrence of Enterococcus faecium (VREF) with high-level resistance to vancomycin (MIC greater than or equal to 64 mu g ml(-1)) on poultry and pig farms. The investigations were conducted as retrospective cohort studies, where groups of farms exposed or not exposed to avoparcin between September 1994 and April 1995 were compared. In poultry, the association between the use of avoparcin and the occurrence of VREF was confounded by the use of broad-spectrum antibiotics, and the adjusted relative risk was 2.9 (1.4-5.9). In pigs, the association had a similar magnitude with a non-adjusted relative risk of 3.3 (0.9-12.3). The similar findings in the two studies provide evidence in favour of a causal association between the use of avoparcin and the occurrence of VREF on farms, and suggest that food animals constitute a potential reservoir of infection for VREF in humans.
Original languageEnglish
JournalPreventive Veterinary Medicine
Volume31
Issue number1-2
Pages (from-to)95-112
ISSN0167-5877
DOIs
Publication statusPublished - 1997

Fingerprint Dive into the research topics of 'Avoparcin used as a growth promoter is associated with the occurrence of vancomycin-resistant Enterococcus faecium on Danish poultry and pig farms'. Together they form a unique fingerprint.

Cite this